Therapy Area topics
Cardiovascular
Bayer’s big kidney disease readout approaches
Bayer has invested heavily in finerenone in kidney disease, but the window of opportunity has narrowed. Data will soon show whether it has shut completely.
Central Nervous System
EAN 2020 – Atara’s multiple sclerosis plan slowly takes shape
Two progressive multiple sclerosis subjects in a high-dose six-patient cohort given ATA188 have seen their disease reverse.
Rett failure sets up thin pipeline
Newron’s failure in Rett syndrome leaves the late-stage pipeline to GW Pharma, Acadia and Anavex.
Diabetes
Novo’s Nash play takes shape
As semaglutide looks set to move into pivotal trials in Nash, Novo Nordisk lays out hopes for longer-term benefits.
Bayer’s big kidney disease readout approaches
Bayer has invested heavily in finerenone in kidney disease, but the window of opportunity has narrowed. Data will soon show whether it has shut completely.
Digital Health
Philips sells the household goods and could spend on tech instead
Digital health is a core focus for Philips. Might more acquisitions be on the way?
Livongo enters the medtech float hall of fame
The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.
Oncology
How best to develop a liquid biopsy?
Natera’s cancer blood test is couture, but Guardant’s pret-a-porter offering might sell better.
Asco 2020 movers – cell therapy companies dominate the risers
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
Respiratory
The scramble to reinvent the ventilator
As Smiths Group delays its split partly so it can focus on ventilator production, the US FDA grants emergency authorisation to other breathing devices to treat Covid-19.
Various
US FDA approval tracker: several early decisions in May
Last month the FDA greenlit four oncology approvals early and the first GnRH antagonist in uterine fibroids.
Go or no go? Oncology dominates upcoming decisions
Astrazeneca’s Lynparza is due US approval decisions in prostate and ovarian cancers, while Bristol's Opdivo’s fate will be determined in lung cancer.
